Shire’s (SHPG) Baxalta unit must pay Bayer (BAYRY) $155.2M in royalties for infringing a patent for hemophilia treatment Adynovate, Bloomberg reports, citing a verdict from a federal court in Wilmington, Delaware. Jurors rejected Shire’s contention that the patent is invalid, Bloomberg adds.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.